<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00455416</url>
  </required_header>
  <id_info>
    <org_study_id>Dietary intervention FL</org_study_id>
    <nct_id>NCT00455416</nct_id>
  </id_info>
  <brief_title>Dietary Intervention in Follicular Lymphoma</brief_title>
  <acronym>KLYMF</acronym>
  <official_title>Dietary Intervention in Stage III/IV Follicular Lymphoma. Impact on Markers of Cell Proliferation, Apoptosis, Host Immune Cell Infiltrate and Oxidative Stress.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A dietary intervention study in patients with Follicular Lymphoma (FL) Stage III/IV to assess&#xD;
      the ability of several dietary factors to induce apoptosis, inhibit cell proliferation and&#xD;
      modulate tumor cell infiltrate in vivo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dietary factors plays an important role in the prevention of several diseases. The&#xD;
      cardiovascular disease mortality have dropped dramatically the last 20 years, but the&#xD;
      relative death rates from cancer remains fairly stable. There is reason to believe that&#xD;
      factors in the tumors microenvironment is of great importance for the outcome of many&#xD;
      malignant diseases, including FL. Factors predicting a poor outcome are associated with&#xD;
      inflammation, oxidative stress which both impair the hosts immune response and produces&#xD;
      growth stimulatory signals. In this open study with 45 patients to be included we seek to&#xD;
      perform a dietary intervention with comparison of apoptosis rate, proliferation rate and&#xD;
      immune cell infiltrate before and after the intervention period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2007</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Anticipated">April 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Apoptosis an proliferation rate in tumor cells,</measure>
    <time_frame>At the end of intervention (week 16)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Levels of: proinflammatory cytokines,tumor immune cell infiltrate</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Follicular Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega 3 fatty acids (EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid))</intervention_name>
    <description>1000mgx5 daily</description>
    <other_name>Nycoplus omega-3 1000mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selenium (L-Selenomethionine),</intervention_name>
    <description>100mcgx2 daily</description>
    <other_name>Solaray selenium 100mcg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Garlic extract (Allicin)</intervention_name>
    <description>6 garlic pearls daily</description>
    <other_name>Circuline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomegranate juice (ellagic acid)</intervention_name>
    <description>Pomegranate juice 100%, 660ml /495 ml every second day.</description>
    <other_name>Produced by:Tine Meierier.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Grape juice (resveratrol, quercetin)</intervention_name>
    <description>Merlot grape juice 100%, 660ml /495 ml every second day</description>
    <other_name>Produced by Tine Meierier</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Green Tea (Epigallocathechin gallate)</intervention_name>
    <description>Green Tea. 2 cups daily</description>
    <other_name>Green tea - twinings java green tea</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years or more.&#xD;
&#xD;
          -  Permanent address in Norway, located in health region south or east. People living&#xD;
             outside these areas in other health regions in Norway may be able to participate but&#xD;
             after individual evaluation.&#xD;
&#xD;
          -  Histologically verified follicular lymphoma grade I or II without clinical signs of&#xD;
             transformation to aggressive lymphoma.&#xD;
&#xD;
          -  Stage III/IV.&#xD;
&#xD;
          -  Previously untreated or at least 1 year since rituximab treatment or 6 months since&#xD;
             cytotoxic chemotherapy.&#xD;
&#xD;
          -  Not scheduled for disease specific treatment for the next 3 months.&#xD;
&#xD;
          -  At least one pathological superficial lymph node available for ultrasound guided&#xD;
             biopsy.&#xD;
&#xD;
          -  Cytologically and/or immunocytologically compatible with follicular lymphoma.&#xD;
&#xD;
          -  Women with childbearing potential, only with use of safe contraceptives&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Gross abnormalities in blood samples. (Hematologic values Hgb&lt; 10, leukocytes&lt; 2,5,&#xD;
             trombocytes &lt;100, liver enzymes (ALAT,ASAT,GT,ALP) &gt; 2,5 x upper normal&#xD;
             values,bilirubin &gt;35 creatinine &gt;130)&#xD;
&#xD;
          -  Other serious medical illness (unstable cardiovascular disease, unstable pulmonary&#xD;
             disease, uncontrolled diabetes, autoimmunity, chronic infection or other active&#xD;
             cancer).&#xD;
&#xD;
          -  Use of NSAID, ASA the last two weeks prior to enrollment.&#xD;
&#xD;
          -  Use of systemic corticosteroids the last two months prior to enrollment.&#xD;
&#xD;
          -  Regular use of anticoagulants as LMW Heparin or warfarin.&#xD;
&#xD;
          -  Use of carbamazepin, nifedipin and other drugs metabolized with CYP 3A4 where&#xD;
             interaction might cause hazardous side effects which cannot be controlled with serum&#xD;
             measurements or organ function monitoring.&#xD;
&#xD;
          -  Inclusion in another clinical trial which involves medication or nutritional&#xD;
             supplements.&#xD;
&#xD;
          -  Use of complementary medicine/alternative medicine which includes high dose* vitamins&#xD;
             or antioxidants/nutritional supplements 2 weeks prior to sampling procedures .&#xD;
&#xD;
          -  Regularly use of omega 3 fatty acids more than 1g / day&#xD;
&#xD;
          -  History of serious or unstable medical or psychiatric disorder.&#xD;
&#xD;
          -  History of heavy alcohol consumption &gt; 3 units / day.&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Individuals judged by the clinical investigator to be unable to follow instructions&#xD;
             and procedures of the study.&#xD;
&#xD;
        (*high dose is defined as vitamins or antioxidant supplements exceeding what is present in&#xD;
        regular multi-vitamin supplements covering regular RDAs)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harald Jr. Holte, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>RRHF Rikshospitalet Radiumhospitalet HF</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kjell Magne Russnes, MD</last_name>
    <phone>+4722934000</phone>
    <email>k.m.russnes@medisin.uio.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Harald Jr. Holte, MD, PhD</last_name>
    <phone>+4722934000</phone>
    <email>harald.holte@radiumhospitalet.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>RRHF RIkshospitalet Radiumhospitalet HF</name>
      <address>
        <city>Montebello</city>
        <state>Oslo</state>
        <zip>0310</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kjell Magne Russnes, MD</last_name>
      <phone>+4722934000</phone>
      <email>k.m.russnes@medisin.uio.no</email>
    </contact>
    <contact_backup>
      <last_name>Harald JR Holte, MD, PhD</last_name>
      <phone>+4722934000</phone>
      <email>harald.holte@radiumhospitalet.no</email>
    </contact_backup>
    <investigator>
      <last_name>Harald Jr Holte, Md, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kjell Magne Russnes, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>April 2007</verification_date>
  <study_first_submitted>April 2, 2007</study_first_submitted>
  <study_first_submitted_qc>April 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2007</study_first_posted>
  <last_update_submitted>May 20, 2008</last_update_submitted>
  <last_update_submitted_qc>May 20, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2008</last_update_posted>
  <responsible_party>
    <name_title>Harald Holte MD, PhD</name_title>
    <organization>Rikshospitalet-Radiumhospitalet HF</organization>
  </responsible_party>
  <keyword>Low grade lymphoma</keyword>
  <keyword>Diet</keyword>
  <keyword>Antioxidants</keyword>
  <keyword>Non Hodgkin Lymphoma - Follicular Lymphoma grade 1&amp;2 stage III/IV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Selenium</mesh_term>
    <mesh_term>Allicin</mesh_term>
    <mesh_term>Resveratrol</mesh_term>
    <mesh_term>Quercetin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

